(Circulation. 2004;110:2896-2902.)
© 2004 American Heart Association, Inc.
Molecular Cardiology |
From the Division of Cardiovascular Surgery, Department of Surgery (M.O., Y.S., N.F., H.I., H.M.), and the Division of Molecular Regenerative Medicine, Department of Regenerative Medicine, Course of Advanced Medicine (S.M., K.B., T.N.), Osaka University Graduate School of Medicine, Osaka, Japan.
Correspondence to Dr Yoshiki Sawa, Division of Cardiovascular Surgery, Department of Surgery, Osaka University, Graduate School of Medicine, Yamada-Oka 2-2, Suita, 565-0871, Osaka, Japan. E-mail sawa{at}surg1.med.osaka-u.ac.jp
Received February 8, 2004; de novo received May 16, 2004; accepted July 27, 2004.
Background Pulmonary hypertension (PH) is a progressive disease characterized by raised pulmonary vascular resistance, thought to be curable only through lung transplantation. Pathophysiologically, proliferation of pulmonary artery smooth muscle cells triggers pulmonary arterial stenosis and/or regurgitation, especially in advanced PH.
Methods and Results Using a rat model of advanced pulmonary vascular disease produced by injecting monocrotaline, we show that hepatocyte growth factor (HGF) targets pulmonary arterioles and blocks the progression of PH. In these rats, endogenous HGF production was dramatically downregulated during developing experimental PH, but c-Met/HGF receptor was abundant in the medial layers of pulmonary arterioles. HGF gene transfection 2 weeks after the monocrotaline injection resulted in milder medial hyperplasia in lung arterioles and inhibited overgrowth of pulmonary artery smooth muscle cells. Notably, exogenous HGF reduced lung expression levels of endothelin-1 and transforming growth factor-ß, which are critically involved in PH-linked fibrogenic events. Overall, medial wall thickening of pulmonary arteries was almost completely prevented by HGF, and the total collagen deposition in the lung decreased; both effects contributed to the suppression of pulmonary artery hypertension.
Conclusions Our results suggest that the loss of endogenous HGF may be a feature of the pathogenesis of PH and that HGF supplementation may minimize pathological lung conditions, even advanced PH.
Key Words: gene therapy pulmonary vasculature growth factor remodeling
This article has been cited by other articles:
![]() |
F. Kamezaki, H. Tasaki, K. Yamashita, M. Tsutsui, S. Koide, S. Nakata, A. Tanimoto, M. Okazaki, Y. Sasaguri, T. Adachi, et al. Gene Transfer of Extracellular Superoxide Dismutase Ameliorates Pulmonary Hypertension in Rats Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 219 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ito, T. Okada, J. Mimuro, H. Miyashita, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, M. Takahashi, U. Ikeda, et al. Adenoassociated Virus Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats Hypertension, September 1, 2007; 50(3): 531 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. Raymond, A. C. Cruz, and G. H. Caughey Mast Cell and Neutrophil Peptidases Attack an Inactivation Segment in Hepatocyte Growth Factor to Generate NK4-like Antagonists J. Biol. Chem., January 20, 2006; 281(3): 1489 - 1494. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |